Epigenetische Therapien in der Krebsbehandlung: Chancen und Herausforderungen

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Forum

• Publication date

  2025-01-06

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s12312-024-01411-z
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials

  2024cited by this paper
• EZH2-mediated development of therapeutic resistance in cancer.

  2024cited by this paper
• Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial

  2024cited by this paper
• Cancer epigenetics: from laboratory studies and clinical trials to precision medicine

  2024influential reference
• TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer

  2022cited by this paper
• DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.

  2022cited by this paper
• Tazemetostat: EZH2 Inhibitor

  2022cited by this paper
• Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer

  2021cited by this paper
• Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors

  2021cited by this paper
• Epigenetic Therapeutic Strategies to Target Molecular and Cellular Heterogeneity in Pancreatic Cancer

  2021cited by this paper
• EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6

  2020cited by this paper
• Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.

  2020cited by this paper
• Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti–PD-1 Resistance in Head and Neck Cancer

  2019cited by this paper
• Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

  2019cited by this paper
• Discovery of a first-in-class EZH2 selective degrader

  2019cited by this paper
• EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

  2019cited by this paper
• Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.

  2019cited by this paper
• Pharmacological inhibition of EZH2 combined with DNA-damaging agents interferes with the DNA damage response in MM cells

  2019cited by this paper
• Epigenetic abnormalities and therapies for hematological malignancies

  2019cited by this paper
• Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

  2019cited by this paper
• Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

  2018cited by this paper
• Magenkarzinom

  2018cited by this paper
• Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy

  2018cited by this paper
• EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer

  2017cited by this paper
• Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.

  2017cited by this paper
• Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?

  2016cited by this paper
• Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells

  2016cited by this paper
• Emerging roles for Polycomb proteins in cancer.

  2016cited by this paper
• Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy

  2015cited by this paper
• The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin

  2015cited by this paper
• The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells.

  2013cited by this paper
• EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma

  2013cited by this paper
• Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.

  2013cited by this paper
• PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation.

  2013cited by this paper
• EZH2 couples pancreatic regeneration to neoplastic progression.

  2012cited by this paper
• EZH2: a pivotal regulator in controlling cell differentiation.

  2012cited by this paper
• PRC2 directly methylates GATA4 and represses its transcriptional activity.

  2012cited by this paper
• Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

  2012cited by this paper
• A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

  2012cited by this paper
• EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

  2012cited by this paper
• Epigenetic Therapies for Cancer

  2011cited by this paper
• Context-Specific Regulation of NFk B Target Gene Expression by EZH 2 in Breast Cancers

  2011cited by this paper
• MEK–ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes

  2011cited by this paper
• Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin

  2010cited by this paper
• Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells

  2007cited by this paper
• Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.

  2006cited by this paper
• EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

  2003cited by this paper
• The polycomb group protein EZH2 is involved in progression of prostate cancer

  2002cited by this paper

• No citing papers are available for this paper.